v3.26.1
Revenues
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
The following table presents a summary of total revenues (in millions): 
Three Months Ended
March 31,
20262025
Xywav$408.2 $344.8 
Xyrem31.2 37.2 
Sleep439.4 382.0 
Epidiolex/Epidyolex249.8 217.7 
Epilepsy249.8 217.7 
Rylaze/Enrylaze103.7 94.2 
Zepzelca101.0 63.0 
Defitelio/defibrotide 47.4 40.7 
Modeyso41.4 — 
Vyxeos26.6 29.5 
Ziihera13.3 2.0 
Oncology333.4 229.4 
Other1
2.7 10.3 
Product sales, net1,025.3 839.4 
High-sodium oxybate AG royalty revenue36.3 48.9 
Other royalty and contract revenues7.3 9.5 
Total revenues$1,068.9 $897.8 
____________________________
(1) Includes Sativex product sales, net for the three months ended March 31, 2025.
The following table presents a summary of total revenues attributed to geographic sources (in millions): 
Three Months Ended
March 31,
20262025
U.S.$959.8 $797.9 
Europe92.4 83.6 
All other16.7 16.3 
Total revenues$1,068.9 $897.8 
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 
Three Months Ended
March 31,
20262025
ESSDS41 %42 %
McKesson12 %11 %
ASD11 %12 %
The percentage of trade receivables by customers who individually accounted for 10% or more of our trade receivables were as follows: 
March 31,
2026		December 31,
2025
ESSDS42 %41 %
ASD16 %16 %
McKesson12 %11 %
Financing and payment
Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 65 days.